Screening and Testing for Homologous Recombination Repair Deficiency (HRD) in Breast Cancer: an Overview of the Current Global Landscape.

IF 4.7 2区医学 Q1 ONCOLOGY

Current Oncology Reports Pub Date : 2024-08-01 Epub Date: 2024-06-01 DOI:10.1007/s11912-024-01560-3

Gordon R Daly, Sindhuja Naidoo, Mohammad Alabdulrahman, Jason McGrath, Gavin P Dowling, Maen M AlRawashdeh, Arnold D K Hill, Damir Varešlija, Leonie Young

{"title":"Screening and Testing for Homologous Recombination Repair Deficiency (HRD) in Breast Cancer: an Overview of the Current Global Landscape.","authors":"Gordon R Daly, Sindhuja Naidoo, Mohammad Alabdulrahman, Jason McGrath, Gavin P Dowling, Maen M AlRawashdeh, Arnold D K Hill, Damir Varešlija, Leonie Young","doi":"10.1007/s11912-024-01560-3","DOIUrl":null,"url":null,"abstract":"Purpose of review: Homologous recombination repair deficiency (HRD) increases breast cancer susceptibility and influences both prophylactic and active management of breast cancer. This review evaluates HRD testing and the therapeutic implications of HRD in a global context.Recent findings: Ongoing research efforts have highlighted the importance of HRD beyond BRCA1/2 as a potential therapeutic target in breast cancer. However, despite the improved affordability of next-generation sequencing (NGS) and the discovery of PARP inhibitors, economic and geographical barriers in access to HRD testing and breast cancer screening do not allow all patients to benefit from the personalized treatment approach they provide. Advancements in HRD testing modalities and targeted therapeutics enable tailored breast cancer management. However, inequalities in access to testing and optimized treatments are contributing to widening health disparities globally.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":null,"pages":null},"PeriodicalIF":4.7000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11300621/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Oncology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11912-024-01560-3","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/1 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Homologous recombination repair deficiency (HRD) increases breast cancer susceptibility and influences both prophylactic and active management of breast cancer. This review evaluates HRD testing and the therapeutic implications of HRD in a global context.

Recent findings: Ongoing research efforts have highlighted the importance of HRD beyond BRCA1/2 as a potential therapeutic target in breast cancer. However, despite the improved affordability of next-generation sequencing (NGS) and the discovery of PARP inhibitors, economic and geographical barriers in access to HRD testing and breast cancer screening do not allow all patients to benefit from the personalized treatment approach they provide. Advancements in HRD testing modalities and targeted therapeutics enable tailored breast cancer management. However, inequalities in access to testing and optimized treatments are contributing to widening health disparities globally.

Abstract Image

查看原文本刊更多论文

乳腺癌同源重组修复缺陷（HRD）的筛查和检测：全球现状概览。

综述的目的：同源重组修复缺陷（HRD）会增加乳腺癌的易感性，并影响乳腺癌的预防和积极治疗。本综述评估了全球范围内的 HRD 检测和 HRD 的治疗意义：正在进行的研究工作凸显了除 BRCA1/2 之外，HRD 作为乳腺癌潜在治疗靶点的重要性。然而，尽管下一代测序技术（NGS）的经济性有所改善，而且发现了 PARP 抑制剂，但由于 HRD 检测和乳腺癌筛查方面的经济和地理障碍，并非所有患者都能从其提供的个性化治疗方法中获益。HRD 检测模式和靶向治疗方法的进步使乳腺癌的治疗变得量身定制。然而，在获得检测和优化治疗方面存在的不平等正在导致全球健康差距的扩大。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Oncology Reports ONCOLOGY-

CiteScore

8.50

自引率

0.00%

发文量

187

审稿时长

6-12 weeks

期刊介绍： This journal aims to review the most important, recently published clinical findings in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care of those affected by cancer. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as cancer prevention, leukemia, melanoma, neuro-oncology, and palliative medicine. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.

文献相关原料

公司名称	产品信息	采购帮参考价格